Pasar al contenido principal

EFECTO DE UNA DIETA MEDITERRANEA RICA EN ACEITE DE OLIVA VIRGEN SOBRE EL RIESGO E INCIDENCIA DE DIABETES MELLITUS TIPO 2: ESTUDIO CORDIOPREV-DIAB

AGL2012-39615

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DE CÓRDOBA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Lipoprotein particle profile in the presence of peripheral artery disease among patients with coronary heart disease: Data from the CORDIOPREV study

  • Cruz Ares, Silvia de la
  • Coronado Carvajal, P.
  • Rangel Zúñiga, Oriol Alberto
  • Torres‑Peña, J.D.
  • Arenas de Larriva, Antonio P.
  • López-Moreno, Alejandro
  • Katsiki, Niki
  • Ordovás, José M.
  • Delgado-Lista, Javier
  • Pérez-Martínez, Pablo
  • Gutiérrez-Mariscal, Francisco M.
  • López-Miranda, José
BACKGROUND: Dyslipidemia is recognized as a contributing factor to peripheral artery disease (PAD). However, the influence of lipoprotein subfractions as compared to traditional serum lipid lev- els is not well-understood. Objective: This study explores the association between lipoprotein subfractions and the occurrence of PAD in patients with coronary heart disease (CHD). METHODS: In the CORDIOPREV study, 981 patients were categorized based on PAD diagnosis, determined by an ankle-brachial index (ABI) ≤0.9. Those with ABI >0.9 and <1.4 were consid- ered PAD-free, while patients with ABI ≥1.4 were excluded. We employed high-throughput nuclear magnetic resonance (NMR) spectroscopy to analyze the concentration and lipid content of lipoprotein subfractions. RESULTS: PAD patients exhibited significantly lower levels of medium high-density lipoprotein (HDL) particles and reduced concentrations of associated lipids within these subfractions except for triglycerides. A higher concentration of large or medium HDL particles correlated with a lower PAD prevalence (odds ratio [OR]: 0.61, 95% CI, 0.44-0.84; OR: 0.59, 95% CI, 0.43-0.81, respectively). In multivariate logistic regression, medium HDL particle levels inversely associated with PAD presence (OR: 0.69, 95% CI, 0.48–0.99, P = .044) after adjustment for confounding factors. CONCLUSIONS: The presence of PAD among CHD patients inversely correlates with medium HDL particle concentrations as determined by NMR. These insights could advance our understanding of PAD pathophysiology and HDL metabolism.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dietary Lipid Quantity and Quality Modulate the Postprandial Metabolomic Profile in Patients with Metabolic Syndrome

  • Mora-Ortiz, Marina
  • Yubero-Serrano, Elena María
  • Priego-Capote, Feliciano
  • Gutiérrez-Mariscal, Francisco Miguel
  • Alcalá-Díaz, Juan F.
  • Torres-Peña, José D.
  • Arenas de Larriva, Antonio Pablo
  • Delgado-Lista, Javier
  • Pérez-Martínez, Pablo
  • Roche, Helen M.
  • López-Miranda, José
16 Páginas.-- 4 Figuras, The literature on the postprandial metabolic changes in individuals with Metabolic Syndrome (MetS) remains limited, despite the fact that postprandial states represent the most common physiological condition in Western societies., The study has been supported by LIPGENE—an EU 6th Framework Program Integrated Project (FOOD-CT- 39 03-505944). The study was also co-financed by the Ministry of Economy and Competitiveness (AGL2012-39615/ALI) and the Carlos III Institute of Health, Spain (PIE14/000015/5), and by the Directorate General for Assessment and Promotion of Research and the EU’s European Regional Development Fund. CIBEROBN is an initiative of the Carlos III Institute of Health, Madrid, Spain., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Modulation of circulating levels of advanced glycation end products and its impact on intima-media thickness of both common carotid arteries: CORDIOPREV randomised controlled trial

  • Gutiérrez-Mariscal, Francisco Miguel
  • López-Moreno, Alejandro
  • Torres-Peña, José D.
  • Gómez-Luna, Purificación
  • Arenas-de Larriva, Antonio P.
  • Romero-Cabrera, Juan Luis
  • Luque, Raúl M.
  • Uribarri, Jaime
  • Pérez-Martínez, Pablo
  • Delgado-Lista, Javier
  • Yubero-Serrano, Elena María
  • López-Miranda, José
16 Páginas.-- 5 Figuras.-- 2 Tablas, Background: Increasing evidence supports the role of advanced glycation end products (AGEs) in atherosclerosis in both diabetic and non-diabetic patients, suggesting that therapeutic strategies targeting AGEs may offer potential benefits in this population. The Mediterranean diet is associated with improved biomarkers and anthropometric measurements related with atherosclerosis in addition to its ability to modulate AGE metabolism. Our aim was to determine whether the reduction in atherosclerosis progression (measured by changes in intima-media thickness of both common carotid arteries (IMT-CC)), observed after consumption of a Mediterranean diet compared to a low-fat diet, is associated with a modulation of circulating AGE levels in patients with coronary heart disease (CHD). Methods: 1002 CHD patients were divided in: (1) Non-increased IMT-CC patients, whose IMT-CC was reduced or not changed after dietary intervention and (2) Increased IMT-CC patients, whose IMT-CC was increased after dietary intervention. Serum AGE levels (methylglyoxal–MG and Nε-Carboxymethyllysine-CML) and parameters related to AGE metabolism (AGER1 and GloxI mRNA and sRAGE levels) and reduced glutathione (GSH) levels were measured before and after 5-years of dietary intervention. Results: The Mediterranean diet did not affect MG levels, whereas the low-fat diet significantly increased them compared to baseline (p = 0.029), leading to lower MG levels following the Mediterranean diet than the low-fat diet (p < 0.001). The Mediterranean diet, but not the low-fat diet, produced an upregulation of AGE metabolism, with increased AGER1 and GloxI gene expression as well as increased GSH and sRAGE levels in Non-increased IMT-CC patients (all p < 0.05). Although the Mediterranean diet increased MG levels in Increased IMT-CC patients, this increment was lower compared to the low-fat diet (all p < 0.05). Conclusions: Our results suggest that an improvement in modulation of AGE metabolism, which facilitates better management of circulating AGE levels, may be one of the mechanisms through which the Mediterranean diet, compared to a low-fat diet, reduces the progression of atherosclerosis in patients with CHD. Trial registration https://clinicaltrials.gov/ct2/show/NCT00924937, Clinicaltrials.gov number, NCT00924937. Graphical abstract: (Figure presented.)., The CORDIOPREV study was supported by the Fundación Patrimonio Comunal Olivarero(Cordioprev-CEAS, 1/2016 to Jose Lopez-Miranda). This study also received research grants from Ministerio de Ciencia e Innovación (AGL2012-39615, AGL2015-67896-P and PID2019-104362RB-I00funded by MCIN/AEI/1.0.13039/501100011033 to Jose Lopez-Miranda), from Consejería de Salud-Junta de Andalucía (PC-0283-2017 to Elena M. Yubero-Serrano) and FIS (PI18/01822 and PI21/00383 toElena M Yubero-Serrano), funded by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union. Elena M Yubero-Serrano was the recipient of the Nicolas Monardes Programme from the“Servicio Andaluz de Salud, Junta de Andalucia”, Spain (C1-0005-2019). Francisco M Gutierrez-Mariscal is supported by a CIBEROBN postdoctoral research contract. The funding bodies had no role in thestudy design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Differences in splicing factors may predict type 2 diabetes remission in the CORDIOPREV study

  • Ojeda-Rodríguez, Ana
  • Torres-Peña, José D.
  • Arenas de Larriva, Antonio Pablo
  • Rangel-Zúñiga, Oriol Alberto
  • Podadera-Herreros, Alicia
  • Boughanem, Hatim
  • García, Miguel E. G.
  • López-Moreno, Alejandro
  • Katsiki, Niki
  • Luque, Raúl M.
  • Pérez-Martínez, Pablo
  • Delgado-Lista, Javier
  • Yubero-Serrano, Elena María
  • López-Miranda, José
12 Páginas.-- 4 Figuras, Alternative splicing is a post-transcriptional process resulting in multiple protein isoforms from a single gene. Abnormal splicing may lead to metabolic diseases, including type 2 diabetes mellitus (T2DM). To identify the splicing factor expression that predicts T2DM remission in coronary heart disease (CHD) patients, we identified newly diagnosed T2DM at baseline (n = 190) from the CORDIOPREV study. Patients were classified as Responders (T2DM remission during 5 years without antidiabetic drugs) or non-Responders. Baseline dysregulation in 5 splicing factors (MBNL1, RBM5, hnRNP G/RBMX, CD44, NT5E) distinguished Responders from non-Responders. Adding these factors to clinical variables [AUC = 0.67], insulin resistance, and beta-cell indexes [AUC = 0.76], improved T2DM remission prediction [AUC = 0.80]. Cox regression analysis showed those with higher remission scores had a 2.63-fold increased remission probability. To conclude, a set of splicing factors that contribute to predicting T2DM remission in patients with CHD has been identified. Further research is needed to elucidate these findings' clinical relevance., The CORDIOPREV study is supported by the Fundación Patrimonio Comunal Olivarero (Cordioprev-CEAS, 1/2016 to J.L.-M.). The main sponsor was not involved in the design or carrying out the study, and its participation was limited to funding and providing the olive oil used in the study. This study also received research grants from Ministerio de Ciencia e Innovación (AGL2012-39615, AGL2015-67896-P and PID2019-104362RB-I00 funded by MCIN/AEI/1.0.13039/501100011033 to J.L.-M.), from Consejería de Salud-Junta de Andalucía (PC-0283-2017 to E.M.Y.-S.) and FIS (PI18/01822 and PI21/00383 to E.M.Y.-S.), integrated into the framework of the National Plan for Scientific Research, Technological Development and Innovation 2013–2016, co-financed by the Instituto de Salud Carlos III (ISCIII) of Spain and also by the Directorate General for Assessment and Promotion of Research and the EU’s European Regional Development Fund (FEDER). A.O.-R. and H.B. were the recipients of Sara Borrell grants (CD21/00099 and CD22/00053, respectively) from the ISCIII. The funding bodies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. We would like to thank the EASP (Escuela Andaluza de Salud Publica), Granada (Spain), for carrying out the randomization process in this study. The CIBEROBN is an initiative of the Instituto de Salud Carlos III, Madrid, Spain. The authors declare no competing interests. The authors read and approved the final manuscript., Peer reviewed